Acute myocardial infarction market hits $1.60b in 2025 across leading markets

Seven major markets record 1.5-million heart attack cases in 2025.

The acute myocardial infarction (AMI) treatment market will expand 13% annually from 2026 to 2036, driven by rising cardiovascular disease prevalence, a growing elderly population, and new therapeutic development, according to DelveInsight.

It reached a market valuation of $1.60b in 2025 across the leading markets, with the US holding the largest market share in the year, ahead of the EU4 countries—Germany, France, Italy, and Spain—the UK, and Japan.

The seven major markets recorded 1.5 million incident AMI cases in 2025, with case numbers expected to rise over the forecast period, 829,000 of which were from the US.

Rising incidence of obesity, diabetes, and hypertension continues to increase AMI burden, whilst population growth and improved diagnostic capability also contribute to higher case detection.

Clinical advances in percutaneous coronary intervention, coronary artery bypass grafting, and intravascular imaging support treatment outcomes and expand therapeutic use.

Standard treatment for acute myocardial infarction uses medicines that help stop blood clots from forming, reduce strain on the heart, lower cholesterol levels, and support heart function after a heart attack.

These include blood thinners, cholesterol-lowering drugs, and medicines that help control blood pressure and relax blood vessels.

Several companies are also developing new treatments aimed at improving how quickly patients can be treated during a heart attack.

Research is also expanding into new areas such as clot-targeting treatments, inflammation control, and gene-based approaches.

NSTEMI cases account for about 75% of all acute myocardial infarction cases across major markets, making it the most common type of heart attack.